Cosmetic Procedures on Deeper Skin Tones: Where the Risk Actually Sits

There is a version of the cosmetic consultation that goes badly for patients with deeper skin tones, and it rarely goes badly because someone refused to treat them. It goes badly because the practitioner treated them exactly the way they treat everyone else. The settings that clear a sun spot on pale skin, the peel depth that produces a nice result on a Fitzpatrick II patient, the incision placed for convenience rather than for scar behavior: each of those choices carries a different risk profile in skin that carries more melanin, and none of that shows up in a price quote. The result is a category of complication that is almost entirely predictable and therefore almost entirely avoidable, which makes it one of the more frustrating patterns in aesthetic medicine.

The correction is not caution for its own sake. Patients with skin of color get excellent outcomes from lasers, peels, injectables, and surgery every day. The correction is specificity: knowing which biological differences are real, which are folklore, and what a competent plan looks like when the practitioner is actually accounting for them.

Melanin does not make skin fragile. It makes it reactive.

The short answer: people with deeper skin tones do not have more melanocytes, they have melanocytes that produce larger and more dispersed melanosomes, and the clinically relevant consequence is a stronger pigmentary response to inflammation rather than any weakness in the skin itself.

This distinction matters because the two ideas lead to opposite advice. Skin that is fragile should be treated gently and less often. Skin that is pigment-reactive should be treated with the same effectiveness but with inflammation treated as the primary variable to control. The second framing is the accurate one. Melanocyte density is broadly comparable across skin tones. What differs is melanosome size, melanin content, and how readily those melanocytes upregulate production when something irritates them. Any insult that triggers inflammation, whether that is a laser pass, a peel, a needle track, acne, an incision, or a bad reaction to a topical, can leave behind post-inflammatory hyperpigmentation. In deeper skin tones that mark is darker, larger, and slower to resolve, and it can persist for months to years rather than weeks.

That single mechanism explains most of what follows. It is also why the most common bad outcome in this population is not a burn or a scar. It is a brown patch where the treatment was, which the patient reads as the procedure having made things worse. From their perspective it did.

It is worth naming the limits of the tool everyone uses to sort this out. The Fitzpatrick scale was developed in the mid-1970s to predict how skin would respond to ultraviolet light during phototherapy dosing, and the higher categories were added later to accommodate brown and black skin. It was never designed to predict laser response, and it maps poorly onto ethnicity and onto the actual constitutional pigment of many patients. A practitioner who has your Fitzpatrick type has one input. A practitioner who has your Fitzpatrick type, your history of hyperpigmentation after previous injuries, and your family history of keloids has the three that matter.

The device choice is where most of the damage is decided

The short answer: melanin in the epidermis competes for the energy a device intended to deliver to a deeper target, so wavelength, pulse duration, fluence, density, and cooling all have to shift, and the practices with good records in deeper skin tones own a different set of machines rather than merely dialing down the ones they have.

Selective photothermolysis works by picking a wavelength that a specific target absorbs more than its surroundings do. That logic gets crowded in darker skin because epidermal melanin absorbs strongly in the shorter visible wavelengths. A 532 nm or 755 nm device aimed at a pigmented lesion or a hair follicle in Fitzpatrick V skin deposits a meaningful fraction of its energy in the epidermis on the way down. The established workaround is longer wavelengths, which penetrate deeper and are absorbed less by epidermal melanin. This is why the 1064 nm Nd:YAG has been the workhorse for laser hair removal in deeper skin tones for two decades, and it is why practices that do this work well tend to have one.

The other levers are less discussed and matter nearly as much:

• Pulse duration. Longer pulses spread energy delivery over time, allowing the epidermis to shed heat rather than accumulate it.
• Density and coverage. With fractional resurfacing, the treated fraction of the surface drives the inflammatory load more than the depth setting does. Lower density with more sessions is the conservative and generally correct trade in skin of color.
• Cooling. Contact cooling, cryogen spray, and cooled tips protect the epidermis specifically, which is exactly the layer at risk here.
• Ablative versus non-ablative. Fully ablative resurfacing carries the highest hyperpigmentation risk of anything in the laser cabinet, and in Fitzpatrick IV through VI most experienced practitioners reach for non-ablative fractional devices, radiofrequency microneedling, or chemical exfoliation instead.
• The test spot. Treating a small inconspicuous area and waiting several weeks is the single most underused safety step in the field. It costs one visit and it converts an assumption into information.

Chemical peels follow the same logic through a different mechanism. Superficial peels using glycolic or salicylic acid have a long and reassuring record across all skin tones. Medium-depth trichloroacetic acid peels and deeper phenol-based work carry a materially higher hyperpigmentation risk in darker skin, and are where priming the skin beforehand with a retinoid and a pigment-suppressing agent moves from optional to standard.

"

The most common bad outcome in skin of color is not a burn or a scar. It is a brown patch exactly where the treatment was, and the patient experiences it as the procedure having failed.

"

Keloid risk changes the arithmetic of any elective incision

The short answer: keloid and hypertrophic scar formation is substantially more common in people of African, Asian, Hispanic, and Middle Eastern descent, which means the decision about whether to make an elective incision at all, and where to put it, deserves more weight than the decision about which suture to use.

Published prevalence estimates vary enormously depending on the population studied and how keloids were defined, but the direction is consistent across a century of dermatologic literature: several fold higher in more pigmented skin, with the strongest single predictor being personal or family history. Anatomy matters too. The presternal chest, the shoulders and deltoid area, the upper back, the jawline, and the earlobes are high-risk sites in anyone and disproportionately so in patients predisposed to keloids. The face away from the jaw, the eyelids, and the palms are comparatively low risk.

That geography has direct consequences for procedure planning. A breast augmentation incision can be placed in the inframammary fold, around the areola, or through the axilla, and the risk profiles are not identical for a patient with a keloid history. Otoplasty and any earlobe work sit in one of the worst neighborhoods on the body for keloid formation, and the better practices say so out loud and plan prophylaxis rather than discovering the problem at the three-month visit. Preventive strategies with reasonable support include closing the wound without tension, silicone sheeting or gel started once the wound has closed, early intralesional corticosteroid for a scar that begins to thicken, and in higher-risk cases pressure therapy. What no plan can offer is the reassurance that a keloid-prone patient will scar like a keloid-resistant one.

Aftercare carries more of the outcome than patients expect

The short answer: in deeper skin tones the weeks after a procedure determine the pigmentary result nearly as much as the procedure itself, and the highest-yield interventions are aggressive sun and visible light protection plus early treatment of any inflammation rather than waiting to see whether it settles.

One finding deserves more attention than it gets from patients. Ultraviolet light is not the only part of the spectrum that drives pigmentation in darker skin. Visible light, the wavelengths that ordinary sunscreens were never built to block, has been shown in controlled studies to induce pigmentation that is more sustained in more pigmented skin. This is the reason tinted sunscreens containing iron oxides outperform conventional mineral or chemical formulations for melasma and post-inflammatory hyperpigmentation in skin of color. It is also the reason "I stay out of the sun" is an incomplete answer, since visible light passes through windows and comes off screens. A tinted broad-spectrum product used daily for months after a resurfacing procedure is doing real work, not cosmetic work.

The rest of the protocol is unglamorous and effective: keep the treated area moist and undisturbed while it heals, do not pick, treat any developing inflammation early rather than stoically, resume pigment-suppressing topicals on the schedule the practitioner sets rather than when the skin feels normal, and protect a new surgical scar from sun for a full year, because incisions in deeper skin tones darken readily and that darkening is often what the patient notices rather than the scar's width.

The experience gap is a real variable, and it is a fair question to ask

The short answer: analyses of dermatology teaching materials have repeatedly found darker skin substantially underrepresented in textbook and journal imagery, which means a practitioner's familiarity with treating skin of color is a function of their actual patient population rather than something guaranteed by their training.

This is not an accusation aimed at any individual clinician. It is a structural fact about how the field has taught itself, and several published image audits of widely used dermatology texts have found images of dark skin in a small minority of photographs, commonly in the range of one in ten. Combine that with the reality that laser and device treatments are frequently delegated to non-physician operators under supervision rules that vary by state, and the range of competence a patient may encounter is wide.

The practical move is not to interrogate credentials in the abstract. It is to ask about volume and outcomes in your specific skin type, look at photographs of patients who look like you, and treat a practice that cannot produce either as a practice that has not done this work often. A surgeon or dermatologist who treats a diverse population will find these questions completely ordinary, because their patients ask them constantly.

The honest summary

Deeper skin tones are not a contraindication to anything in aesthetic medicine. They are a set of specific parameters that a competent practitioner adjusts for, and the adjustments are well described: longer wavelengths, longer pulse durations, lower densities, epidermal cooling, shallower peels or proper priming, test spots, keloid-aware incision planning, and an aftercare protocol that takes visible light seriously. None of that is exotic. It is the difference between a practice that has treated thousands of patients across the full range of skin tones and one that owns a single device and applies one protocol to everyone.

The reasonable expectation at a consultation is that your skin type comes up before the price does, and that it comes up in the form of technical specifics rather than reassurance. If a practitioner names your Fitzpatrick type, asks whether previous injuries or acne left dark marks, asks about keloids in your family, proposes a test spot, and describes what they would do if hyperpigmentation appeared, you are in the right room. If your skin tone is never mentioned at all, that silence is the most useful piece of information in the entire appointment.